Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatment
Data files
Apr 10, 2025 version files 34.44 KB
-
DLS_0_month.xlsx
20.91 KB
-
README.md
5.96 KB
-
Volume_of_spheroids_Fig_2b-c.csv
3.49 KB
-
Volume_of_spheroids_Fig_5b-c.csv
4.07 KB
Abstract
The development of novel and effective treatment strategies, particularly through drug combinations, can significantly enhance therapeutic outcomes. This study explores the innovative combination of resveratrol (RES), a phenolic compound, with sunitinib (SUNI), a multi-target tyrosine kinase inhibitor, for targeting HT-29 colon cancer cells. We identified a synergistic effect at a SUNI ratio of 1:8, based on their IC50 values. Increasing the dosage of the combined treatment led to a notable reduction in cell viability, observed in both two-dimensional (2D) and three-dimensional (3D) cell cultures. To improve resveratrol therapeutic efficacy, drug-loaded polymeric nanoparticles (PLGA-RES) were successfully fabricated with an average diameter of 178.4 ± 4.6 nm. The combination of PLGA-RES and free SUNI at the optimal ratio exhibited enhanced anticancer activity, reducing cell viability by approximately 25% and 15% more than PLGA-RES and free SUNI alone, respectively, in 2D cultures. Moreover, this combination therapy demonstrated superior effectiveness in treating HT-29 spheroids over 24 and 48 hours. These findings highlight the potential of this combined approach to improve colorectal cancer treatment outcomes.
Dataset DOI: 10.5061/dryad.k3j9kd5jb
Description of the data and file structure
DLS and volume of spheroids
(https://doi.org/10.5061/dryad.k3j9kd5jb)
We have uploaded the raw dynamic light scattering (DLS) size distribution data for polymeric nanoparticles, including poly(lactic-co-glycolic acid) (PLGA) and resveratrol-loaded polymeric nanoparticles (PLGA-RES) (DLS 0 month.xlsx). Additionally, the data on spheroid volumes after treatment with the combination drug (Volume of spheroids_Fig 2b-c.csv) and nanoparticles (Volume of spheroids_Fig 5-bc.csv) have been uploaded.
Files and variables
1. DLS 0 month.xlsx
1.1 DLS particle size distribution data:
Samples: PLGA and PLGA-RES (Table 2)
Measurements: Three repeat measurements for each sample at the temperature of 25 ℃
Variables:
Size (d.nm)_(1): Particle size in nanometers for the first measurement
Intensity (Percent)_(1): Intensity for the first measurement
Size (d.nm)_(2): Particle size in nanometers for the second measurement
Intensity (Percent)_(2): Intensity for the second measurement
Size (d.nm)_(3): Particle size in nanometers for the third measurement
Intensity (Percent)_(3): Intensity for the third measurement
1.2 Zeta potential data:
Samples: PLGA and PLGA-RES (Table 2)
Measurements: Three repeat measurements for each sample at the temperature of 25 ℃
Variables:
Zeta Potential (mV)_(1): Zeta potential in millivolts for the first measurement
Total Counts_(1): Intensity for the first measurement
Zeta Potential (mV)_(2): Zeta potential in millivolts for the second measurement
Total Counts_(2): Intensity for the second measurement
Zeta Potential (mV)_(3): Zeta potential in millivolts for the third measurement
Total Counts_(3): Intensity for the third measurement
2. Volume of spheroids_Fig 2b-c.csv
Raw data of spheroid’s volume for Figure 2b-c in the Article
The treated spheroid sizes were observed by inverted microscopy. The diameters of the spheroid edges were measured using ImageJ software. The data were change to radius and calculated the spheroid volume by the following equation;
V = (4/3)πr3
Where r is the radius of spheroid.
Sample treated for Figure 2b,c: the combination of resveratrol (RES) and sunitinib (SUNI) at different concentration
Measurements: Three repeat measurements for each spheroid
Variables:
Control: Spheroid diameter of untreated sample (e.g., Control_1: Untreated sample for sample 1; Control_6: Untreated sample for sample 6)
SUNI:RES_4:32 : Spheroid diameter of treated sample with 4 uM SUNI and 32 uM RES (e.g., SUNI:RES_4:32_1: Treated sample with 4 uM SUNI and 32 uM RES for sample 1; SUNI:RES_4:32_4: Treated sample with 4 uM SUNI and 32 uM RES for sample 4)
SUNI:RES_8:64 : Spheroid diameter of treated sample with 8 uM SUNI and 64 uM RES (e.g., SUNI:RES_8:64_1: Treated sample with 8 uM SUNI and 64 uM RES for sample 1; SUNI:RES_8:64_3: Treated sample with 8 uM SUNI and 64 uM RES for sample 3)
SUNI:RES_16 :128 : Spheroid diameter of treated sample with 16 uM SUNI and 128 uM RES (e.g., SUNI:RES_16:128_1: Treated sample with 16 uM SUNI and 128 uM RES for sample 1; SUNI:RES_16:128_5: Treated sample with 8 uM SUNI and 64 uM RES for sample 5)
Diameter 1: Diameter in µm for first measurement
Diameter 2: Diameter in µm for second measurement
Diameter 3: Diameter in µm for third measurement
3. Volume of spheroids_Fig 5b-c.csv
Raw data of spheroid’s volume for Figure 5b, c in the Article
The treated spheroid sizes were observed by inverted microscopy. The diameters of the spheroid edges were measured using ImageJ software. The data were change to radius and calculated the spheroid volume by the following equation;
V = (4/3)πr3
Where r is the radius of spheroid.
Sample treated for Figure 5b, c: the combination of resveratrol (RES) and sunitinib (SUNI) at different concentration
Measurements: Three repeat measurements for each spheroid
Variables:
Control: Spheroid diameter of untreated sample (e.g., Control_1: untreated sample for sample 1; Control_6: untreated sample for sample 6)
Unloaded: Spheroid diameter of treated sample with unloaded nanoparticles (e.g., Unloaded _1: Treated sample with 2 mg/mL of unloaded nanoparticles for sample 1; Unloaded _2: Treated sample with 2 mg/mL of unloaded nanoparticles for sample 2)
PLGA-RES: Spheroid diameter of treated sample with PLGA-RES (e.g., PLGA-RES_1: Treated sample with 2 mg/mL of PLGA-RES for sample 1; PLGA-RES_3: Treated sample with 2 mg/mL of PLGA-RES for sample 3)
SUNI: Spheroid diameter of treated sample with 16 uM free SUNI (e.g., SUNI_1: Treated sample with 16 uM free SUNI for sample 1; SUNI_5: Treated sample with 16 uM free SUNI for sample 5)
PLGA-RES+SUNI: Spheroid diameter of treated sample with combination of PLGA-RES and free SUNI (e.g., PLGA-RES+SUNI_1: Treated sample with combination of 2 mg/mL PLGA-RES and 16 uM free SUNI for sample 1; PLGA-RES+SUNI_2: Treated sample with combination of 2 mg/mL PLGA-RES and 16 uM free SUNI for sample 2)
Diameter 1: Diameter in µm for first measurement
Diameter 2: Diameter in µm for second measurement
Diameter 3: Diameter in µm for third measurement
Particle size, polydispersity index (PDI), and zeta potential of NPs were investigated by a Zetasizer.
Treated spheroid sizes were observed by inverted microscopy and measured using ImageJ software. After that, the volume of spheriods was calculated.